Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Rosas (REMDACTA)
  NCT04409262		 RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
434/215 inconclusive
  • inconclusive 3 % decrease in hospital discharge (PE) with a moderate degree of certainty due to some concern in risk of bias
COVACTA (Rosas)
  NCT04320615		 RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
301/151 suggested
  • inconclusive 19 % increase in clinical improvement,clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
NCT04377750 (HMO-0224-20) unpublished
  NCT04377750		 RCTtocilizumab placeboCOVID-19 severe or criticallyhigh
37/17 inconclusive

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons